Feliza Mirasol

Late-stage and commercial biomanufacturing pose a challenge to cell-culture processing.

Biosimilars and biobetters have their own unique manufacturing strategies and challenges.

Single-use technologies have become increasingly prevalent in final fill/finish operations for biologics.

Aseptic fill/finish is crucial in biopharma manufacturing and is optimized through automated technology.

Higher cell titers and cell densities have posed a challenge to cell harvesting, a crucial step in biologics manufacturing.

Successful outsourcing relationships for early phase analytics in drug development are driven by partnership.

Spectroscopic tools present an alternative method for reliable at-line process monitoring and control.

Biologic new molecular entities (NMEs) accounted for 26% of total NME approvals in 2017.

Single-use technologies are starting to gain ground as capacity needs change, but industrywide adoption remains low.

Conducting stability testing on APIs/finished drug product helps ensure shelf-life storage.

Recent investments show expansion activity in cell culture facilities.

A quality-by-design approach that implements PAT offers advantages in upstream cell-culture processing.

A roundtable Q&A with biopharma executives elucidates the challenges posed by single-use bioreactor bags in contributing to extractables and leachables in the biomanufacturing process.

The Biomanufacturing Technology Roadmap is accelerating innovative manufacturing strategies for biopharmaceuticals.

Small-molecule therapeutics can also benefit from the implementation of PAT in the manufacturing process.

The use of therapeutic vaccines presents a new way to manage diseases, such as cancer and sexually transmitted diseases.

Connectors are a critical element in the process optimization of single-use bioprocessing systems.

Despite the disappointing therapeutic performance of ADCs thus far, the pipeline still boasts promising prospects.

Process analytical testing for biopharmaceuticals requires enhanced methods due to complex bioprocesses.

The development of emerging therapies poses unique manufacturing and formulation challenges for drug developers as candidates like cell and gene therapies advance through the pipeline.